Campaign

CRO#: 730153

Embryomic

MedTech

Embryomic has developed a patent-protected test, PMT-BC, which selects the most viable IVF embryo for successful transfer to the mother as an implant resulting in pregnancy.
by Robert Brennan
Dublin
185% Funded
€ 500,000 Funding goal
€ 923,800 Invested
57Investors


Company Summary :

 

The Embryomic proprietary test, PMT-BC, is based on 12 years of development data and utilises mass spectrometry (MALDI-ToF MS) to analyse recently fertilised embryos (blastocysts). The test of new blastocysts is calibrated/checked against thousands of digitally stored spectra/biomarkers and uploaded into a predictive algorithm. This patented (2020) algorithm identifies the most metabolically competent/viable embryo for IVF transfer (to mother) and will reduce IVF treatment cycles (time to pregnancy), costs and emotional stress for prospective parents.

 

Key highlights:

  • IVF as a fertility treatment is growing globally in importance.
  • Only 25-30% of IVF treatment cycles succeed.
  • PMT-BC Test developed over 20 years of research with IVF clinics, subjecting 12,000 spent blastocysts(embryos) to MALDI-ToF mass spectrometry over 12 years and building a digital spectra library for use in predictive algorithm. 
  • Patents granted in EU, UK and China
  • Lab established 2024 in DCU Innovation Campus 
  • Validation studies of PMT-BC have started at a large Irish IVF Clinic chain, SIMS, and has received ethics approval from its parent company in Australia.
  • Progress is being made with a German clinic to participate in a parallel validation study. 

 

  • Campaign Story
  • Team
  • Documents
  • FAQ
  • Updates
  • Discussion

Risk warning

Investing in start-ups and early-stage businesses involves significant risks, including illiquidity, lack of dividends, loss of capital and dilution. Such investments should only be made as part of a well-diversified portfolio.

The service offered by Spark Venture Funding is intended solely for investors who are sufficiently knowledgeable and experienced to understand these risks and to make their own investment decisions. You will only be able to invest in opportunities on the Spark Venture Funding platform once you have been assessed as sufficiently sophisticated.

Investment opportunities presented on the platform are not offers to the public. Investments can only be made by registered members of Spark Venture Funding, based on the information provided by the companies raising capital. Neither Spark Venture Funding nor any of its representatives accepts responsibility for this information or for any recommendations or opinions made by the companies. We strongly recommend that all private investors seek advice from a qualified professional advisor before investing in any opportunity on the Spark Venture Funding platform.

Please click here to read our full Risk Warning.

Spark Venture Funding is authorised by the Central Bank of Ireland.